OBJECTIVE: In comparison with stem cell transplantation using bone marrow or cytokine-mobilized peripheral blood, cord blood transplantation is characterized by delayed engraftment, in particular platelet recovery. The differences in the kinetics of engraftment may be related to quantitative differences in the numbers of stem cells and megakaryocyte progenitor cells and/or to qualitative differences between megakaryocyte progenitor cells in these grafts. We compared the hematopoietic composition of these grafts and determined the distribution of mature and immature megakaryocyte progenitor cells in cord blood and mobilized peripheral blood and their in vitro kinetic behavior. METHODS: Megakaryocyte progenitor cell subpopulations from cord blood (CB) and mobilized peripheral blood (PBSC) were expanded in vitro in the presence of mpl-ligand. The developmental differences during expansion of megakaryocyte progenitors were analyzed by flow cytometry and progenitor assays. RESULTS: We found that the immature (CD34(+)/CD41(-)) subpopulation from CB contains more than 98% of all megakaryocyte progenitor cells, responsible for 99% of all megakaryocytic cells cultured during 2 weeks. The CB CD34(+)/CD41(+) subpopulation shows no contribution to megakaryocytic cell formation. In contrast, in PBSC the mature (CD34(+)/CD41(+)) subpopulation contains 7% of all megakaryocyte progenitor cells. Moreover, CD34(+) cells from CB and PBSC also showed distinct phenotypic differences during maturation in vitro. PBSC megakaryocyte progenitor cells transiently express both CD34 and CD41 during maturation in vitro, whereas CB progenitor cells transiently lack expression of both markers before differention into (CD34(-)/CD41(+)) megakaryocytic cells. CONCLUSION: The in vitro data indicate the presence of different developmental stages of megakaryocyte progenitor cells in CB as compared to PBSC. These differences in composition and maturation between CB and PBSC may be related to the different kinetics of engraftment following transplantation of these stem cell sources.
OBJECTIVE: In comparison with stem cell transplantation using bone marrow or cytokine-mobilized peripheral blood, cord blood transplantation is characterized by delayed engraftment, in particular platelet recovery. The differences in the kinetics of engraftment may be related to quantitative differences in the numbers of stem cells and megakaryocyte progenitor cells and/or to qualitative differences between megakaryocyte progenitor cells in these grafts. We compared the hematopoietic composition of these grafts and determined the distribution of mature and immature megakaryocyte progenitor cells in cord blood and mobilized peripheral blood and their in vitro kinetic behavior. METHODS: Megakaryocyte progenitor cell subpopulations from cord blood (CB) and mobilized peripheral blood (PBSC) were expanded in vitro in the presence of mpl-ligand. The developmental differences during expansion of megakaryocyte progenitors were analyzed by flow cytometry and progenitor assays. RESULTS: We found that the immature (CD34(+)/CD41(-)) subpopulation from CB contains more than 98% of all megakaryocyte progenitor cells, responsible for 99% of all megakaryocytic cells cultured during 2 weeks. The CB CD34(+)/CD41(+) subpopulation shows no contribution to megakaryocytic cell formation. In contrast, in PBSC the mature (CD34(+)/CD41(+)) subpopulation contains 7% of all megakaryocyte progenitor cells. Moreover, CD34(+) cells from CB and PBSC also showed distinct phenotypic differences during maturation in vitro. PBSC megakaryocyte progenitor cells transiently express both CD34 and CD41 during maturation in vitro, whereas CB progenitor cells transiently lack expression of both markers before differention into (CD34(-)/CD41(+)) megakaryocytic cells. CONCLUSION: The in vitro data indicate the presence of different developmental stages of megakaryocyte progenitor cells in CB as compared to PBSC. These differences in composition and maturation between CB and PBSC may be related to the different kinetics of engraftment following transplantation of these stem cell sources.
Authors: Mark van der Garde; Anneke Brand; Manon C Slot; Alice de Graaf-Dijkstra; Jaap Jan Zwaginga; Yvette van Hensbergen Journal: Stem Cells Dev Date: 2015-03-13 Impact factor: 3.272
Authors: Paul J Simmons; Simon N Robinson; Mark F Munsell; Michael W Thomas; Jeannie A Javni; Nathalie Brouard; Patrick A Zweidler-McKay; Elizabeth J Shpall Journal: Stem Cells Dev Date: 2015-03-18 Impact factor: 3.272
Authors: Joshua Kellner; Sufang Li; Patrick A Zweidler-McKay; Elizabeth J Shpall; Ian McNiece Journal: Cytotherapy Date: 2014-12-19 Impact factor: 5.414
Authors: Swapna Panuganti; Alaina C Schlinker; Paul F Lindholm; Eleftherios T Papoutsakis; William M Miller Journal: Tissue Eng Part A Date: 2013-01-14 Impact factor: 3.845
Authors: Mark van der Garde; Yvette van Hensbergen; Anneke Brand; Manon C Slot; Alice de Graaf-Dijkstra; Arend Mulder; Suzanne M Watt; Jaap Jan Zwaginga Journal: Stem Cells Dev Date: 2015-01-01 Impact factor: 3.272
Authors: Mark van der Garde; Melissa van Pel; Jose Eduardo Millán Rivero; Alice de Graaf-Dijkstra; Manon C Slot; Yoshiko Kleinveld; Suzanne M Watt; Helene Roelofs; Jaap Jan Zwaginga Journal: Stem Cells Dev Date: 2015-10-08 Impact factor: 3.272